HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
Open accessThe DOI matches its Crossref record; 53 of the 56 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a major component of the immune-suppressive network described in cancer and many other pathological conditions. We demonstrate that although MDSCs from peripheral lymphoid organs and the tumor site share similar phenotype and morphology, these cells display profound functional differences. MDSC from peripheral lymphoid organs suppressed antigen-specific CD8+ T cells but failed to inhibit nonspecific T cell function. In sharp contrast, tumor MDSC suppressed both antigen-specific and nonspecific T cell activity. The tumor microenvironment caused rapid and dramatic up-regulation of arginase I and inducible nitric oxide synthase in MDSC, which was accompanied by down-regulation of nicotinamide adenine dinucleotide phosphate–oxidase and reactive oxygen species in these cells. In contrast to MDSC from the spleen, MDSC from the tumor site rapidly differentiated into macrophages. Exposure of spleen MDSC to hypoxia resulted in the conversion of these cells to nonspecific suppressors and their preferential differentiation to macrophages. Hypoxia-inducible factor (HIF) 1α was found to be primarily responsible for the observed effects of the tumor microenvironment on MDSC differentiation and function. Thus, hypoxia via HIF-1α dramatically alters the function of MDSC in the tumor microenvironment and redirects their differentiation toward tumor-associated macrophages, hence providing a mechanistic link between different myeloid suppressive cells in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia can abolish the cell killing activity of NK cells, which correlates with an increase in HIF-1α [78].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [78]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“tumor hypoxia generates macrophages that can suppress T cell responses. This suppressive phenotype is mediated by hypoxic induction of arginase 1 and nitric oxide synthase, both that restrict T cell activation. Strikingly, induction of this hypoxic pathway in macrophages is required for optimal tumor growth [84, 85].”
From Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function (2013) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, tumor hypoxia and/or HIFs can attract myeloid-derived suppressor cells (Corzo et al., 2010), regulatory T-cells (Clambey et al., 2012), and tumor-associated macrophages (Doedens et al., 2010;Imtiyaz et al., 2010) with immunosuppressive functions.”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Corzo et al., 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which suggests that 32-134D inhibited the expression of these latter mRNAs in immune or other stromal cell types, where HIFs are known to play critical roles (56–61), rather than in tumor cells.”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [56]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 2×
“Extensive studies in recent years suggested several mechanisms of MDSC-mediated immune suppression that involve arginine (Bronte and Zanovello, 2005; Rodríguez and Ochoa, 2008) and cysteine (Srivastava et al., 2010) metabolism, expression of some surface molecules (Pan et al., 2010), up-regulation…”
BackgroundMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Self-citationSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationAlmand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Self-citationMovahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
Cited by
Items 501–600 of 1,000
Khouzam, R. A., Janji, B., Thiery, J., Zaarour, R. F., Chamseddine, A. N., Mayr, H., Savagner, P., Kiéda, C., Gad, S., Buart, S., et al. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.008 · Cited by 58
Zhang, K., Zakeri, A., Alban, T. J., Dong, J., Ta, H. M., Zalavadia, A. H., Branicky, A., Zhao, H., Jurić, I., Husic, H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113661 · Cited by 62
Kim, Y.-S., Kim, Y.-J., Lee, J.-M., Kim, E.-K., Park, Y.-J., Choe, S.-K., Ko, H.-J., & Kang, C.-Y. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103040 · Cited by 51
Myeloid-derived cells are key targets of tumor immunotherapy
Medina‐Echeverz, J., Aranda, F., & Berraondo, P. (2014) · OncoImmunology · doi:10.4161/onci.28398 · Cited by 55
In VitroandIn VivoAnticancer Effects of Sterol Fraction from Red AlgaePorphyra dentata
Kazłowska, K., Lin, H. V., Chang, S., & Tsai, G. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/493869 · Cited by 66
Mesenchymal-myeloid interaction in the regulation of immunity
Cheung, T. S., & Dazzi, F. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.01.002 · Cited by 54
Katayama, Y., Tachibana, M., Kurisu, N., Oya, Y., Terasawa, Y., Goda, H., Kobiyama, K., Ishii, K. J., Akira, S., Mizuguchi, H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700435 · Cited by 52
Koustas, E., Sarantis, P., Kyriakopoulou, G., Papavassiliou, A. G., & Karamouzis, M. V. (2019) · Cancers · doi:10.3390/cancers11040533 · Cited by 54
Lin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 55
Microglia and macrophages in glioblastoma: landscapes and treatment directions
Solomou, G., Young, A. M. H., & Bulstrode, H. J. C. J. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13657 · Cited by 58
The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes
Duechler, M., Pęczek, Ł., Żuk, K., Zaleśna, I., Jeziorski, A., & Czyż, M. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.09.003 · Cited by 49
Eruslanov, E. B., Daurkin, I., Vieweg, J., Daaka, Y., & Kusmartsev, S. A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.033 · Cited by 48
Würdinger, T., Deumelandt, K., van der Vliet, H. J., Wesseling, P., & de Gruijl, T. D. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.003 · Cited by 58
Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 52
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Xu, Y., He, L., Fu, Q., & Hu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759015 · Cited by 52
de la Calle‐Fabregat, C., Calafell-Segura, J., Gardet, M., Dunsmore, G., Mulder, K., Ciudad, L., Silvin, A., Moreno‐Càceres, J., Corbí, A. L., Muñoz‐Pinedo, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adq5226 · Cited by 54
Deng, Z., Cheng, Z., Xiang, X., Yan, J., Zhuang, X., Liu, C., Jiang, H., Ju, S., Zhang, L., Grizzle, W. E., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.023 · Cited by 55
Zhang, Y., Bi, Y., Yang, H., Chen, X., Liu, H., Lu, Y., Zhang, Z., Liao, J., Yang, S., Chu, Y., et al. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.0913473 · Cited by 48
Hatziioannou, A., Alissafi, T., & Verginis, P. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-493r · Cited by 47
Tsutsumi, C., Ohuchida, K., Katayama, N., Yamada, Y., Nakamura, S., Okuda, S., Otsubo, Y., Iwamoto, C., Torata, N., Horioka, K., et al. (2024) · Gastric Cancer · doi:10.1007/s10120-023-01456-4 · Cited by 53
Yang, Q., Qiu, H., Xie, H., Qi, Y., Cha, H., Qu, J., Wang, M., Feng, Y., Ye, X., Mu, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601860 · Cited by 47
Radiotherapy-induced tumor physical microenvironment remodeling to overcome immunotherapy resistance
Peng, J., Yin, X., Yun, W., Meng, X., & Huang, Z. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216108 · Cited by 48
Ibáñez-Vea, M., Zuazo, M., Gato, M., Arasanz, H., Fernández-Hinojal, G., Escors, D., & Kochan, G. T. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0492-4 · Cited by 47
Chouaïb, S., Umansky, V., & Kiéda, C. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73874 · Cited by 51
Comparative Immunology and Immunotherapy of Canine Osteosarcoma
Mason, N. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_14 · Cited by 52
Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation
Gorvel, L., & Olive, D. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101671 · Cited by 51
Tumour, Oxidative Stress and Host T Cell Response: Cementing the Dominance
Bhattacharyya, S., & Saha, J. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12350 · Cited by 46
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy
Kamran, N., Chandran, M., Lowenstein, P. R., & Castro, M. G. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.10.008 · Cited by 52
Myeloid‐derived suppressor cells mediate tolerance induction in autoimmune disease
Wegner, A., Verhagen, J., & Wraith, D. C. (2017) · Immunology · doi:10.1111/imm.12718 · Cited by 51
Adah, D., Yang, Y., Liu, Q., Gadidasu, K. K., Tao, Z., Yu, S., Dai, L., Li, X., Zhao, S., Qin, L., et al. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0342-6 · Cited by 48
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus
Dorhoi, A., Kotzé, L. A., Berzofsky, J. A., Sui, Y., Gabrilovich, D. I., Garg, A., Hafner, R., Khader, S. A., Schaible, U. E., Kaufmann, S. H. E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci136288 · Cited by 47
Self-citationDavidov, V., Jensen, G. L., Mai, S., Chen, S., & Pan, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01842 · Cited by 47
Leonard, W., Dufait, I., Schwarze, J. K., Ka, L. L., Engels, B., Jiang, H., Berge, D. V. D., Gevaert, T., Storme, G. A., Verovski, V. N., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.01.014 · Cited by 44
Understanding the tumour micro‐environment communication network from an NOS2/COX2 perspective
Basudhar, D., Bharadwaj, G., Somasundaram, V., Cheng, R. Y. S., Ridnour, L. A., Fujita, M., Lockett, S., Anderson, S. K., McVicar, D. W., & Wink, D. A. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14488 · Cited by 45
Roles of Myeloid-Derived Suppressor Cell Subpopulations in Autoimmune Arthritis
Li, M., Zhu, D., Wang, T., Xia, X., Tian, J., & Wang, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02849 · Cited by 45
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
Ling, Z., Yang, C. H., Tan, J., Dou, C., & Chen, Y. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03966-9 · Cited by 44
Poulaki, A., Piperaki, E., & Voulgarelis, M. (2021) · Microorganisms · doi:10.3390/microorganisms9040759 · Cited by 54
Overcoming physical stromal barriers to cancer immunotherapy
Chung, S. W., Xie, Y., & Suk, J. S. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01036-y · Cited by 54
Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors
Pettinella, F., Mariotti, B., Lattanzi, C., Bruderek, K., Donini, M., Costa, S. E., Marini, O., Iannoto, G., Gasperini, S., Caveggion, E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101380 · Cited by 50
Burgers, F. H., van der Mijn, J. C., Seijkens, T. T. P., Jedema, I., Bex, A., & Haanen, J. B. A. G. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00983-w · Cited by 60
Tumor microenvironment in glioblastoma: The central role of the hypoxic–necrotic core
Bayona, C., Ranđelović, T., & Ochoa, I. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218216 · Cited by 59
Myeloid cell diversification and complexity: an old concept with new turns in oncology
Chioda, M., Peranzoni, E., Desantis, G., Papalini, F., Falisi, E., Solito, S., Mandruzzato, S., & Bronte, V. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9268-1 · Cited by 47
Cardoso, M. S., Silva, T. M., Resende, M., Appelberg, R., & Borges, M. C. (2015) · Infection and Immunity · doi:10.1128/iai.00144-15 · Cited by 47
Cha, H.-R., Lee, J. H., Hensel, J. A., Sawant, A., Davis, B. H., Lee, C. M., Deshane, J. S., & Ponnazhagan, S. (2016) · The Prostate · doi:10.1002/pros.23155 · Cited by 44
Goffaux, G., Hammami, I., & Jolicœur, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-10464-1 · Cited by 52
Circulating and tumor‑infiltrating myeloid‑derived suppressor cells in cervical carcinoma patients
Wu, L., Liu, H., Guo, H., Wu, Q., Yu, S., Qin, Y., Wang, G., Wu, Q., Zhang, R., Wang, L., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.8532 · Cited by 45
Recent advances in exosome-based immunotherapy applied to cancer
Xie, J., Zheng, Z., Tuo, L., Deng, X., Tang, H., Peng, C., & Zou, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296857 · Cited by 40
Panagi, M., Mpekris, F., Voutouri, C., Hadjigeorgiou, A. G., Symeonidou, C., Porfyriou, E., Michael, C., Stylianou, A., Martin, J. D., Cabral, H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0246 · Cited by 53
Inflammation and Myeloid Cells in Cancer Progression and Metastasis
Deng, J., & Fleming, J. B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.759691 · Cited by 47
Targeting the Hypoxia-Sensing Pathway in Clinical Hematology
Forristal, C. E., & Lévesque, J.-P. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0134 · Cited by 46
Kheshtchin, N., & Hadjati, J. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30643 · Cited by 44
Bryant, J., Lerret, N. M., Wang, J.-J., Kang, H.-K., Tasch, J., Zhang, Z., & Luo, X. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302771 · Cited by 39
Dynamics of the spleen and its significance in a murine H22 orthotopic hepatoma model
Li, B., Zhang, S., Huang, N., Chen, H., Wang, P., Li, J., Pu, Y., Yang, J. J., & Li, Z. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216638772 · Cited by 41
Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology
Sica, A., & Strauss, L. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.4mr1116-476r · Cited by 42
Fang, Z., Wen, C., Chen, X., Yin, R., Zhang, C., Wang, X., & Huang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17013 · Cited by 45
Metabolic regulation of suppressive myeloid cells in cancer
Sica, A., Strauss, L., Consonni, F. M., Travelli, C., Genazzani, A. A., & Porta, C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.002 · Cited by 40
Myeloid-derived suppressor cells in non-neoplastic inflamed organs
Sendo, S., Saegusa, J., & Morinobu, A. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0076-7 · Cited by 40
Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies
Dewhirst, M. W., Mowery, Y. M., Mitchell, J. B., Cherukuri, M. K., & Secomb, T. W. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126044 · Cited by 41
Turning ‘Cold’ tumors ‘Hot’: immunotherapies in sarcoma
Rytlewski, J. D., Milhem, M. M., & Monga, V. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6041 · Cited by 42
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Emerging roles of MITF as a crucial regulator of immunity
Lee, A., Lim, J., & Lim, J. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01175-5 · Cited by 42
Negative Regulation of Myeloid-derived Suppressor Cells in Cancer
Qu, P., Boelte, K. C., & Lin, P. C. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.685538 · Cited by 39
Toussaint, M., Fiévez, L., Drion, P. V., Cataldo, D. D., Bureau, F., Lekeux, P. M., & Desmet, C. J. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.88 · Cited by 44
Myeloid derived suppressor cells and innate immune system interaction in tumor microenvironment
Pramanik, A., & Bhattacharyya, S. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120755 · Cited by 44
Liu, X., Zhao, Y., Wu, X., Liu, Z., & Liu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931104 · Cited by 50
Wang, S.-H., Lu, Q., Guo, Y., Song, Y., Liu, P., & Wang, Y. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.019 · Cited by 41
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2844-6 · Cited by 42
Oxygen-dependent regulation of immune checkpoint mechanisms
Ohta, A. (2018) · International Immunology · doi:10.1093/intimm/dxy038 · Cited by 39
Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC
Horvath, L., Puschmann, C., Scheiber, A., Martowicz, A., Sturm, G., Trajanoski, Z., Wolf, D. G. F., Pircher, A., & Salcher, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.01.010 · Cited by 40
Targeting myeloid regulatory cells in cancer by chemotherapeutic agents
Naiditch, H., Shurin, M. R., & Shurin, G. V. (2011) · Immunologic Research · doi:10.1007/s12026-011-8213-2 · Cited by 42
Myeloid-derived suppressor cells in glioma
Mirghorbani, M., Gool, S. V., & Rezaei, N. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.857603 · Cited by 38
Tumor cells hijack macrophages via lactic acid
Bronte, V. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.67 · Cited by 38
Finkelstein, S. E., Rodriguez, F., Dunn, M. W., Farmello, M.-J., Smilee, R. C., Janssen, W. E., Kang, L., Chuang, T., Seigne, J. D., Pow‐Sang, J. M., et al. (2012) · Immunotherapy · doi:10.2217/imt.12.24 · Cited by 37
Self-citationNon-coding RNAs rewire cancer metabolism networks
Lin, X., Wu, Z., Hu, H., Luo, M., & Song, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.019 · Cited by 37
The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers
Midavaine, É., Côté, J., & Sarret, P. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09974-2 · Cited by 40
Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Bayık, D., Bartels, C. F., Lovrenert, K., Watson, D. C., Zhang, D., Kay, K. E., Lee, J., Lauko, A. J., Johnson, S., Lo, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3840 · Cited by 36
Xu, T., Liu, Z., Huang, L., Jing, J., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1057850 · Cited by 39
Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells
Goldmann, O., & Medina, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1461455 · Cited by 47
Immune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 40
Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells
Goulart, M. R., Hlavaty, S. I., Chang, Y., Polton, G. A., Stell, A. J., Perry, J. A., Wu, Y., Sharma, E., Broxholme, J., Lee, A. C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40285-3 · Cited by 41
Qian, X., Zhang, Q., Shao, N., Shan, Z., Cheang, T., Zhang, Z., Su, Q., Wang, S., & Lin, Y. (2019) · Europe PMC (PubMed Central) · Cited by 36
Xie, Z., Ikegami, T., Ago, Y., Okada, N., & Tachibana, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1734268 · Cited by 37
Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy
Coleman, M. F., Cozzo, A. J., Pfeil, A. J., Etigunta, S. K., & Hursting, S. D. (2020) · Cancers · doi:10.3390/cancers12040852 · Cited by 38
Liang, H., & Shen, X. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.137 · Cited by 42
Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis
Monti, M., Vescovi, R., Consoli, F., Farina, D., Moratto, D., Berruti, A., Specchia, C., & Vermi, W. (2020) · Cancers · doi:10.3390/cancers12082085 · Cited by 38
Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer
Nisar, S., Bhat, A. A., Hashem, S., Yadav, S. K., Rizwan, A., Singh, M. K., Bagga, P., Macha, M. A., Frenneaux, M. P., Reddy, R. D., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02656-7 · Cited by 38
Li, X., Li, Y., Yu, Q., Qian, P., Huang, H., & Lin, Y. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0421-597rr · Cited by 41
Targeting Myeloid Suppressive Cells Revives Cytotoxic Anti-Tumor Responses in Pancreatic Cancer
Sarhan, D., Eisinger, S., He, F., Bergsland, M., Pelicano, C., Driescher, C., Westberg, K., Ibarlucea-Benitez, I., Hamoud, R., Palano, G., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105317 · Cited by 38
Monocytes link atherosclerosis and cancer
Pittet, M. J., & Świrski, F. K. (2011) · European Journal of Immunology · doi:10.1002/eji.201141727 · Cited by 40
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.005 · Cited by 36
Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity
Tzeng, H., & Huang, Y.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054422 · Cited by 38
Immunometabolic reprogramming, another cancer hallmark
Kumar, V., & Stewart, J. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125874 · Cited by 36
Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment
Fang, X., Lan, H., Jin, K., & Qian, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149551 · Cited by 39
Lacotte, S., Slits, F., Orci, L. A., Meyer, J., Oldani, G., Delaune, V., Gonelle-Gispert, C., Morel, P., & Toso, C. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1234565 · Cited by 35
Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer
Camisaschi, C., Vallacchi, V., Vergani, E., Tazzari, M., Ferro, S., Tuccitto, A., Kuchuk, O., Shahaj, E., Sulsenti, R., Castelli, C., et al. (2016) · Vaccines · doi:10.3390/vaccines4040038 · Cited by 35
Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa
Chen, Y., Li, Q., Li, X., Ma, D., Fang, J., Luo, L., Liu, X., Wang, X., Lui, V. W. Y., Xia, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1388484 · Cited by 39
Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis
Purohit, A., Saxena, S., Varney, M. L., Prajapati, D. R., Kozel, J. A., Lazenby, A. J., & Singh, R. K. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.01.002 · Cited by 42
HIF-Prolyl Hydroxylase Domain Proteins (PHDs) in Cancer—Potential Targets for Anti-Tumor Therapy?
Gaete, D., Rodriguez, D., Watts, D., Sormendi, S., Chavakis, T., & Wielockx, B. (2021) · Cancers · doi:10.3390/cancers13050988 · Cited by 37
The Dynamics of Interactions Among Immune and Glioblastoma Cells
Éder, K., & Kálmán, B. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8362-x · Cited by 41
Metadata
- Authors
- Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I.
- Affiliations
- University of South Florida (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2010-09-27
- Volume
- 207
- Issue
- 11
- Pages
- 2439-2453
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2964584
- OpenAlex
- W2109424201
- Semantic Scholar
- 77cf3cf3976e026979d2b7acf9b04119740a45f1
- Cited by
- 1,173
- References
- 56
- Citations by year
- 2026: 69 · 2025: 73 · 2024: 69 · 2023: 92 · 2022: 80 · 2021: 109 · 2020: 93 · 2019: 62 · 2018: 83 · 2017: 62 · 2016: 69 · 2015: 51 · 2014: 70 · 2013: 76 · 2012: 61
- FWCI
- 25.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- National Cancer Institute (CA84488, R01CA084488, R01CA103921, R01CA136828, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- myeloid-derived suppressor cells, HIF-1α, tumor microenvironment, hypoxia, tumor-associated macrophages, T cell suppression, arginase-1, inducible nitric oxide synthase, NADPH oxidase, reactive oxygen species, MDSC differentiation, immunosuppression
- MeSH terms
- Aged, Animals, Antigens, Neoplasm, Arginase, Cell Differentiation, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Middle Aged, Neoplasms, Cell Hypoxia, CD8-Positive T-Lymphocytes, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Nitric Oxide Synthase Type II
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.